← Oncology Approval Tracker

FDA DECISION ·

Lanreotide Acetate Injection

lanreotide acetate · Cipla

FDA approvalNew or expanded indicationCarcinoid syndrome
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with carcinoid syndrome, to reduce the need for short-acting somatostatin analog rescue therapy.

LAMPGEN ANALYSIS

Why it matters

The separate lanreotide product gained a symptom-control indication, distinct from an antitumor progression endpoint.

What research teams should watch

Record rescue medication use and symptom burden so treatment changes can be interpreted alongside the injection schedule.

PRIMARY RECORDS

Sources